LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients
Status:
Completed
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
The predominant remaining questions for post-transplant treatment of Hepatitis C virus (HCV)
in the DAA (direct acting anti-virals) era are whether a ribavirin-free regimen is possible
and whether pre-emptive treatment is now a potential option to prevent long-term damage to
the allograft.
Our aim is to provide answers to these primary questions with our multicenter, prospective,
randomized, open-label intent-to-treat phase IV study
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of South Carolina
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Ribavirin Sofosbuvir